Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

SVB Leerink Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $50

SVB Leerink analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $54 to $50.
byBenzinga Newsdesk
December 22, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

SVB Leerink analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $54 to $50.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts